题名 | Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. |
链接 | http://www.bloodjournal.org/content/124/21/1625.full.pdf |
欢迎光临 科研速递论坛 (http://expaper.cn/) | Powered by Discuz! X2.5 |